MEI Pharma, Inc. (MEIP)

Market Cap	49.97M
Revenue (ttm)	58.77M
Net Income (ttm)	-37.87M
Shares Out	6.66M
EPS (ttm)	-5.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,700
Open	7.55
Previous Close	7.55
Day's Range	7.28 - 7.55
52-Week Range	4.00 - 13.60
Beta	1.03
Analysts	Buy
Price Target	33.00 (+340.0%)
Earnings Date	May 11, 2023

About MEIP

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 19, 2003
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: MEIP

Financial Performance

In 2022, MEI Pharma's revenue was $40.70 million, an increase of 16.96% compared to the previous year's $34.80 million. Losses were -$54.45 million, 31.8% more than in 2021.

Analyst Forecast

According to 6 analysts, the average rating for MEIP stock is "Buy." The 12-month stock price forecast is $33.0, which is an increase of 340.00% from the latest price.

Price Target

$33.0

(340.00% upside)

Analyst Consensus: Buy